Loading clinical trials...
Loading clinical trials...
Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia
Conditions
Interventions
GRASPA
L-asparaginase
Locations
28
Belgium
Hopital Des Enfants Reine Fabiola
Brussels, Belgium
Chr de La Citadelle
Liège, Belgium
Chu D'Angers
Angers, France
Hopital Saint Jacques
Besançon, France
Hopital Pellegrin Enfants
Bordeaux, France
Chu Estaing
Clermont-Ferrand, France
Start Date
December 1, 2009
Primary Completion Date
September 1, 2014
Completion Date
October 1, 2016
Last Updated
February 2, 2022
NCT05292664
NCT06316856
NCT05745714
NCT05658640
NCT06034561
NCT05809284
Lead Sponsor
ERYtech Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions